OSIRIS THERAPEUTICS MD (OSIR)

Overview Price 5.03 Price Change Today 0.00 (0.00%) P&P rating Zacks Rank 3 - HOLD Open Price $0.00 Previous Close $5.03 Daily Range $0.00 - $0.00 52-Week Range $4.12 - $8.39 Volume 0 OSIRIS THERAPEUTICS, INC. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells Osteocel for regenerating bone in orthopedic indications. Prochymal is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease and also Crohn's disease, and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. Osiris also has partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. Osiris is a fully integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products. Other Resources for OSIR Detailed Quote Earnings Estimates Company Report Interactive Chart Commentary Zacks Blog: Osiris' Update on Prochymal January 4, 2012 Zacks Blog: Osiris Beats Zacks Consensus November 8, 2011 Zacks Blog: Earnings Miss for Osiris August 11, 2011 Zacks Blog: Osiris Tops on Lower Costs May 11, 2011 Zacks Blog: Osiris Profits Rise on Lower Costs March 10, 2011 OSIRIS THERAPEUTICS, INC. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells Osteocel for regenerating bone in orthopedic indications. Prochymal is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease and also Crohn's disease, and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. Osiris also has partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. Osiris is a fully integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products.   Brokerage Analyst Recommendations 5 Brokerage Firms Covering OSIR   Strong Buy 1 Buy 0 Hold 2 Sell 1 Strong Sell 1 Average Broker Recommendation (ABR): 3.2   OSIR Ratings: BUY  SELL  HOLD OSIR Consensus Forecasts

Rate this Stock! You haven't rated this stock yet! Ticker Call Buy Sell Analysis Time Frame Week or Less Week to a Month One to Three Months Three to Six Months Six Months to a Year One to Three Years Three Plus Years What The Community Thinks Total Players 4 Buy 1 Sell   Top Buy Analysis BUY: OSIR Company: OSIRIS THERAPEUTICS INC. Points: -53.74 Start Price: $6.53 Start Date: 10/02/2009 3:39 PM LordOfPorts P&P Score: 1.67 Recs: Stock's current price presents a great opportunity. Comments: 0 | Comment More Recent Analysis Top Sell Analysis SELL: OSIR Company: OSIRIS THERAPEUTICS INC. Points: 121.36 Start Price: $12.43 Start Date: 04/20/2009 10:50 PM JJONES P&P Score: 99.64 Recs: Comments: 0 | Comment More Recent Analysis

Blog Posts

User	User Score	Date	Title	Comments	Last Comment
Zacks_Analysts	0.00	01/04/12	Osiris' Update on Prochymal - Analyst Blog	0
Zacks_Analysts	0.00	11/08/11	Osiris Beats Zacks Consensus - Analyst Blog	0
Zacks_Analysts	0.00	08/11/11	Earnings Miss for Osiris - Analyst Blog	0
Zacks_Analysts	0.00	05/11/11	Osiris Tops on Lower Costs - Analyst Blog	0
Zacks_Analysts	0.00	03/10/11	Osiris Profits Rise on Lower Costs - Analyst Blog	0
Zacks_Analysts	0.00	11/12/10	Osiris EPS Up on Lower Costs - Analyst Blog	0
Zacks_Analysts	0.00	08/09/10	Osiris Beats on Cost Control - Analyst Blog	0
Zacks_Analysts	0.00	07/29/10	Initiating Coverage of Aastrom Bio - Analyst Blog	0
Zacks_Analysts	0.00	05/14/10	Osiris Beats on Lower Expenses - Analyst Blog	0
Zacks_Analysts	0.00	03/03/10	Osiris Misses Estimates - Analyst Blog	0

Pages: [ 1 ]  2  >>

Commentary

BUY: OSIRIS THERAPEUTICS INC. (OSIR) Start Price: $6.53 Points: -53.74 Created: 10/02/2009 Stock's current price presents a great opportunity. Comments: 0 | Comment LordOfPorts Recs:

SELL: OSIRIS THERAPEUTICS INC. (OSIR) Start Price: $12.43 Points: +121.36 Created: 04/20/2009 Comments: 0 | Comment JJONES Recs:

BUY: OSIRIS THERAPEUTICS INC. (OSIR) Start Price: $12.39 Points: -50.92 Created: 01/01/2008 Comments: 0 | Comment vogs Recs:

BUY: OSIRIS THERAPEUTICS INC. (OSIR) Start Price: $12.74 Points: -52.05 Created: 01/01/2008 Comments: 0 | Comment picman1 Recs:

BUY: OSIRIS THERAPEUTICS INC. (OSIR) Start Price: $22.20 Points: -69.11 Created: 01/01/2008 Comments: 0 | Comment jcovotsos Recs:

Picks

Username	P&P Score	Call	Time Frame	Start Date	Start Price	Today (change)	Stock Gain	S&P Gain	Points	Analysis
LordOfPorts	1.67	BUY	Week or Less	10/02/2009	$6.53	$5.10 (-13.41%)	-21.90%	+31.84%	-53.74	view close
JJONES	99.64	SELL	Week or Less	04/20/2009	$12.43	$5.10 (-13.41%)	-58.97%	+62.39%	+121.36
vogs	84.88	BUY	Six Months to a Year	01/01/2008	$12.39	$5.10 (-13.41%)	-58.84%	-7.92%	-50.92
picman1	43.28	BUY	Six Months to a Year	01/01/2008	$12.74	$5.10 (-13.41%)	-59.97%	-7.92%	-52.05
jcovotsos	57.55	BUY	Six Months to a Year	01/01/2008	$22.20	$5.10 (-13.41%)	-77.03%	-7.92%	-69.11